Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Ann Christine Thastrom
Observed names:
A. Thastrom,
A. Thåström,
AnnChristine Thastrom,
AnnChristine Thåström
Institution:
Genentech
Observed institution:
Genentech
OpenAlex ID:
A5113776538
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
2016
·
Arjun V Balar
, Matthew D Galsky
, et al.
·
The Lancet
·
2,197
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
2020
·
Matthew D Galsky
, José Ángel Arranz Arija
, et al.
·
The Lancet
·
786
High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade
2020
·
Kobe C. Yuen
, Li-Fen Liu
, et al.
·
Nature Medicine
·
431
IMvigor130: Efficacy and safety from a phase III study of atezolizumab (atezo) as monotherapy or combined with platinum-based chemotherapy (PBC) vs placebo + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC)
2019
·
E. Grande
, M. Galsky
, et al.
·
Annals of Oncology
·
39
PDF
Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1.
2016
·
Arjun Vasant Balar
, Matt D. Galsky
, et al.
·
Journal of Clinical Oncology
·
31
IMvigor130: A randomized, phase III study evaluating first-line (1L) atezolizumab (atezo) as monotherapy and in combination with platinum-based chemotherapy (chemo) in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC).
2018
·
Matt D. Galsky
, Enrique Grande
, et al.
·
Journal of Clinical Oncology
·
28
Atezolizumab (atezo) in platinum (plat)-treated locally advanced/metastatic urothelial carcinoma (mUC): Updated OS, safety and biomarkers from the Ph II IMvigor210 study
2016
·
Y. Loriot
, J.E. Rosenberg
, et al.
·
Annals of Oncology
·
24
Comparative Effectiveness of Non-cisplatin First-line Therapies for Metastatic Urothelial Carcinoma: Phase 2 IMvigor210 Study Versus US Patients Treated in the Veterans Health Administration
2018
·
Nancy Vander Velde
, Annie Guerin
, et al.
·
European Urology Oncology
·
22
Author Correction: High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade
2021
·
Kobe C. Yuen
, Li-Fen Liu
, et al.
·
Nature Medicine
·
11
PDF
Atezolizumab (atezo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Outcomes by prior therapy.
2017
·
Jose Luis Perez-Gracia
, Yohann Loriot
, et al.
·
Journal of Clinical Oncology
·
7
Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1.
2016
·
Arjun Vasant Balar
, Matt D. Galsky
, et al.
·
Journal of Clinical Oncology
·
7
Biological features and clinical outcomes in atezolizumab (atezo)-treated patients (pts) with metastatic urothelial cancer (mUC) of the upper vs lower urinary tract (UTUC vs LTUC)
2018
·
M.D. Galsky
, R. Banchereau
, et al.
·
Annals of Oncology
·
6
1142 Efficacy of atezolizumab (MPDL3280A) in platinum-treated metastatic urothelial carcinoma (mUC): Update from the IMvigor 210 phase II clinical trial
2016
·
M. Van Der Heijden
, M. Retz
, et al.
·
European Urology Supplements
·
1
Show more works
View as search
Works count:
13
Citation count:
3,593
H-index:
9
I10-index:
9
Year
Topic
Type
